𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1021 HBSAG LEVELS DURING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS B: PEGINTERFERON VERSUS ENTECAVIR

✍ Scribed by Reijnders, J.G.P.; Rijckborst, V.; Sonneveld, M.J.; Scherbeijn, S.M.J.; Boucher, C.A.B.; Hansen, B.E.; Janssen, H.L.A.

Book ID
122744072
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
50 KB
Volume
52
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum HBeAg quantitation during antivira
Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
✍ Heijtink, Rudolf A.; Kruining, Johannes; Honkoop, Pieter; Kuhns, Mary C.; Hop, W πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

Hepatitis Be antigen (HBeAg) seroconversion is considered the principal short-term goal of antiviral therapy in chronic hepatitis B. To test whether the pre-and per-treatment HBeAg quantitation has a higher predictive value than that of hepatitis B virus DNA (HBV-DNA) quantitation for the outcome of

Clearance of serum HBsAg and anti-HBs se
Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B
✍ Olivier Borgniet; Parviz Parvaz; CΓ©cile Bouix; Philippe Chevallier; Christian Tr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 151 KB

## Abstract In this study, we have analyzed the evolution of serum HBsAg levels in 16 patients with chronic hepatitis B who showed an HBsAg seroconversion following antiviral therapy. The data showed that the clearance of serum HBsAg is slower than that of serum HBV DNA, which may reflect a slow ki